Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Cases of immune checkpoint inhibitors-induced hypophysitis and anterior pituitary insufficiency

From: Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

Variable

Information

 1. Number of Reports

84

 2. Cases

222

 3. Gender

Males = 145; Females = 62; Not reported = 15

 4. Age (years)

Median = 61; Mean + SD = 60.4 + 11.4; Range = 31–85

 5. Pertinent medical history

PHxEndoD: Reported = 12; Not reported = 210

FHxEndoD: Reported = 2; Not reported = 220

PHxAutoD: Reported = 4; Not reported = 218

 6. Type of cancer

Melanoma = 193; Renal cell carcinoma = 6; Prostate carcinoma = 7; non-small cell lung cancer = 5, lung cancer = 5; papillary thyroid carcinoma =1; mesothelioma =1; not reported = 4

 7. Check point inhibitor

ICI Drug D/C?:

Ipilimumab = 188; Nivolumab = 13; Tremelilumab = 4; CTLA-4 = 8; Atezolizumab = 2; Ipilimumab + Nivolumab = 3; Nivolumab, then Ipilimumab = 1; Ipilimumab, then Pembrolizumab = 2; Ipilimumab, then Nivomumab = 1.

Yes = 45 No = 17 Not reported = 160

 8. Clinical presentation

Reflects the hormone(s) affected

 9. Onset (weeks) after first dose

Median = 12; Mean = 13.8 + 10.3; Range 3–76

 10. Biochemical tests

↓ACTH/cortisol = 183;

↓TSH/FT4/FT3 = 172;

↓LH/FSH/T/Estradiol = 137;

↓PRL = 22; ↓GH/IGF-1 = 22. ↑TSH, ↓FT4,/FT3 = 2

 11. Diagnosis (patients with # hormone deficiencies[def])

5 deficiency (def) = 7; 4 def = 14; 3 def = 72; 2 def = 47;

One (isolated) def = 36 (31 ACTH, 4 TSH, 1 LH, FSH def).

3 reports with case series account for remainder

 12. Imaging Brain/Pituitary MRI/CT

Enlarged/Enhanced = 108; Normal 49; Not reported =11; Not done = 11; Sella abnormality = 3; atrophy = 3

3 reports with case series account for remainder

 13. CTCAE grade reported

Yes = 5; Not reported in 217

 14. Therapy at onset at diagnosis

High dose steroids = 144; steroids = 62; no steroids = 7; Not reported = 9

 15. Outcome

219 recovered/discharged (replacement therapy 195 & 24 not reported); 3 deceased.